Turnstone rakes in $11.3 mln Series A in Versant-led round

Turnstone Biologics Inc, a biotech company focused on developing novel oncolytic viral immunotherapies for cancer, has closed $11.3 million in Series A funding. Versant Ventures led the round. In addition to the funding, the company has named Dr. Sammy J. Farah as CEO and Dr. Brian D. Lichty as chief technology officer while adding Dr. Jerel Davis and Dr. Brad Bolzon, a partner and managing director at Versant Ventures respectively, to its board of directors.

North AmericaUSBriefs